

Applicants: Philip O. Livingston and Friedhelm Helling
Serial No.: 08/475,784
Filed : June 7, 1995
Page 2

Amendments to the Claims

This listing of the claims will replace all prior versions and listings of the claims in the application.

Claims 1-100 (Cancelled).

--101. (Currently amended) A composition which comprises:

- a) a conjugate ~~comprising of~~ (i) a GD3 lactone ganglioside derivative which comprises an unaltered oligosaccharide part and an altered ceramide portion comprising an altered sphingosine base and (ii) Keyhole Limpet Hemocyanin ~~or a derivative thereof~~;
- b) a saponin derivable from the bark of a Quillaja saponaria Molina tree; and
- c) a pharmaceutically acceptable carrier;

wherein the amount of the conjugated GD3 lactone ganglioside derivative is an amount between about 1 µg and about 200 µg, the amount of the saponin is an amount of between about 10 µg and about 200 µg, and the GD3 lactone:Keyhole Limpet Hemocyanin molar ratio is from 200:1 to 1400:1, the relative amounts of such conjugate and such saponin being effective to stimulate or enhance production in a subject of an antibody to GD3,

wherein in the conjugate the ganglioside derivative is covalently bound to Keyhole Limpet Hemocyanin ~~or the derivative thereof~~ through a C-4 carbon of the altered sphingosine base of the altered ceramide portion of the ganglioside derivative to an ε-aminolysyl group of Keyhole Limpet Hemocyanin ~~or the derivative thereof~~, wherein the C-4 carbon is present in a CH₂ group; and

Applicants: Philip O. Livingston and Friedhelm Helling
Serial No.: 08/475,784
Filed : June 7, 1995
Page 3

~~wherein the derivative comprises Keyhole Limpet Hemocyanin linked to an immunological adjuvant, a non-ionic block copolymer, or a cytokine. --~~

--102. (Previously presented) The composition of claim 101, wherein the saponin is QS-21. --

Claims 103-107 (Cancelled).

--108. (Currently amended) The composition of claim [[107]] 101, wherein the amount of the saponin is about 100 µg. --

--109. (Currently amended) The composition of claim [[107]] 101, wherein the amount of the saponin is about 200 µg. --

Claim 110 (Cancelled).

--111. (Currently amended) The [[A]] composition of claim 101 which comprises:

- a) a conjugate ~~comprising of~~ (i) a GD3 lactone ganglioside derivative which comprises an unaltered oligosaccharide part and an altered ceramide portion comprising an altered sphingosine base and (ii) Keyhole Limpet Hemocyanin ~~or a derivative thereof~~;
- b) QS-21, a saponin derivable from the bark of a Quillaja saponaria Molina tree, ~~wherein the saponin is QS-21~~; and
- c) a pharmaceutically acceptable carrier;

wherein the conjugated GD3 lactone ganglioside derivative is present in an amount of between about 10 µg and about 50 µg 1 µg and about

Applicants: Philip O. Livingston and Friedhelm Helling
Serial No.: 08/475,784
Filed : June 7, 1995
Page 4

200 µg, the amount of the saponin is about 100 µg and the GD3 lactone: Keyhole Limpet Hemocyanin molar ratio is from 200:1 to 1400:1, and wherein the amount of such conjugate and such saponin is effective to stimulate or enhance production in a subject of an antibody to GD3;

and wherein in the conjugate the ganglioside derivative is covalently bound to Keyhole Limpet Hemocyanin ~~or the derivative thereof~~ through a C-4 carbon of the altered sphingosine base of the altered ceramide portion of the ganglioside derivative to an ε-aminolysyl group of Keyhole Limpet Hemocyanin ~~or the derivative thereof~~, wherein the C-4 carbon is present in a CH₂ group; and

~~wherein the derivative comprises Keyhole Limpet Hemocyanin linked to an immunological adjuvant, a non-ionic block copolymer or a cytokine. --~~

--112. (Previously presented) A method of treating a subject afflicted with melanoma which comprises administering to said subject an amount of the composition of claim 111 effective to stimulate or enhance production of an antibody to GD3 in the subject and to thereby treat said melanoma in said subject. --

--113. (Currently amended) A method of stimulating or enhancing production of an antibody to GD3 in a subject which comprises administering to the subject an effective amount of a composition which comprises:

- a) a conjugate ~~comprising of~~ (i) a GD3 lactone ganglioside derivative which comprises an unaltered oligosaccharide part and an altered ceramide portion comprising an altered sphingosine base and (ii) Keyhole Limpet Hemocyanin ~~or a derivative thereof~~;

Applicants: Philip O. Livingston and Friedhelm Helling
Serial No.: 08/475,784
Filed : June 7, 1995
Page 5

- b) a saponin derivable from the bark of a Quillaja saponaria Molina tree; and
- c) a pharmaceutically acceptable carrier;

wherein the amount of the conjugated GD3 lactone ganglioside derivative is an amount between about 1 µg and about 200 µg, the amount of the saponin is an amount between about 10 µg and about 200 µg, and the GD3 lactone:Keyhole Limpet Hemocyanin molar ratio is from 200:1 to 1400:1, the relative amounts of such conjugate and such saponin being effective to stimulate or enhance production on a subject of an antibody to GD3,

wherein in the conjugate the ganglioside derivative is covalently bound to Keyhole Limpet Hemocyanin ~~or the derivative thereof~~ through a C-4 carbon of the altered sphingosine base of the altered ceramide portion of the ganglioside derivative to an ε-aminolysyl group of Keyhole Limpet Hemocyanin ~~or the derivative thereof~~, wherein the C-4 carbon is present in a CH₂ group, so as to thereby stimulate or enhance production in the subject of the antibody to GD3. --

--114. (Currently amended) A method of treating a human subject having cancer ~~cancer in a subject~~ which comprises administering to the subject an effective ~~cancer-treating~~ amount of a composition which comprises:

- a) a conjugate ~~comprising of~~ (i) a GD3 lactone ganglioside derivative which comprises an unaltered oligosaccharide part and an altered ceramide portion comprising an altered sphingosine base and (ii) Keyhole Limpet Hemocyanin, ~~or a derivative thereof;~~
- b) a saponin derivable from the bark of a Quillaja saponaria Molina tree; and

Applicants: Philip O. Livingston and Friedhelm Helling
Serial No.: 08/475,784
Filed : June 7, 1995
Page 6

c) a pharmaceutically acceptable carrier;

wherein the amount of the conjugated GD3 lactone ganglioside derivative is an amount between about 1 μ g and about 200 μ g, the amount of the saponin is an amount of between about 10 μ g and about 200 μ g, and the GD3 lactone:Keyhole Limpet Hemocyanin molar ratio is from 200:1 to 1400:1, the relative amounts of such conjugate and such saponin being effective to stimulate or enhance production in a subject of an antibody to GD3,

wherein in the conjugate the ganglioside derivative is covalently bound to Keyhole Limpet Hemocyanin ~~or the derivative thereof~~ through a C-4 carbon of the altered sphingosine base of the altered ceramide portion of the ganglioside derivative to an ϵ -aminolysyl group of Keyhole Limpet Hemocyanin ~~or the derivative thereof~~, wherein the C-4 carbon is present in a CH_2 group, so as to thereby stimulate or enhance production of an antibody to GD3 in the subject and thereby treat the cancer. --

--115. (Previously presented) The method of claim 114, wherein the cancer is of epithelial origin. -

--116. (Previously presented) The method of claim 114, wherein the cancer is of neuroectodermal origin. -

--117. (Previously presented) The method of claim 116, wherein the cancer of neuroectodermal origin is a melanoma. --

--118. (Previously presented) The method of claim 113 or 114, wherein the administering is effected at two or more sites. --

Applicants: Philip O. Livingston and Friedhelm Helling
Serial No.: 08/475,784
Filed : June 7, 1995
Page 7

--119. (Previously presented) The method of claim 118, wherein the administering is effected at three sites. -

--120. (Previously presented) The method of claim 113 or 114, wherein the composition is administered subcutaneously to said subject. --

--121. (Previously presented) The method of claim 120, wherein the composition is administered to said subject at two-week intervals. -

--122. (Previously presented) The method of claim 120, wherein the composition is initially administered to said subject at weekly intervals. --

--123. (Previously presented) The method of claim 113 or 114, wherein the composition to be administered is prepared prior to administration to the subject by mixing the conjugate and the saponin. --

--124. (Previously presented) The method of claim 123, wherein the conjugate and the saponin are mixed on the day of administration to the subject. --

Claim 124 (Cancelled).